Anemia in myelofibrosis: Current and emerging treatment options

Francesco Passamonti, Claire N. Harrison, Ruben A. Mesa, Jean Jacques Kiladjian, Alessandro M. Vannucchi, Srdan Verstovsek

Research output: Contribution to journalReview articlepeer-review


Myelofibrosis (MF) is a clonal hematologic malignancy with progressive bone marrow fibrosis. Clinical manifestations of MF include splenomegaly, constitutional symptoms, and anemia, whose pathogenesis is multifactorial and largely due to ineffective erythropoiesis and is clinically associated with poor quality of life and reduced overall survival. The only curative treatment for MF is allogenic stem cell transplantation; however, few patients are eligible. Disease management strategies for MF-related anemia have limited effectiveness, and Janus kinase (JAK) inhibitors may induce or worsen related anemia. Thus, there is a significant unmet need for the treatment of patients with MF-related anemia. This review summarizes current and emerging treatments for anemia in MF, including luspatercept and KER-050 (transforming growth factor-β ligand traps), momelotinib and pacritinib (JAK inhibitors), pelabresib (a bromodomain extra-terminal domain inhibitor), PRM-151 (an antifibrotic agent), imetelstat (a telomerase inhibitor), and navitoclax (a BCL-2/BCL-xL inhibitor). Therapeutic combinations with ruxolitinib may offer another treatment approach.

Original languageEnglish (US)
Article number103862
JournalCritical Reviews in Oncology/Hematology
StatePublished - Dec 2022


  • Anemia
  • Myelofibrosis

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Anemia in myelofibrosis: Current and emerging treatment options'. Together they form a unique fingerprint.

Cite this